- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT00861094
Radiation Therapy + Combination Chemotherapy as 1st-Line Therapy for Patients With Inoperable Esophageal Cancer
Phase II-III Study Comparing Radiochemotherapy With the FOLFOX Regimen Versus Radiochemotherapy With 5FU-cisplatin (Herskovic Regimen) in First Line Treatment of Patients With Inoperable Oesophageal Cancer.
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as oxaliplatin, fluorouracil, leucovorin, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) together with radiation therapy may kill more tumor cells.
PURPOSE: This randomized phase II/III trial is studying radiation therapy and two different combination chemotherapy regimens to compare how well they work as first-line therapy in treating patients with esophageal cancer that cannot be removed by surgery.
연구 개요
상세 설명
OBJECTIVES:
Primary
- To assess the feasibility of radiochemotherapy comprising oxaliplatin, fluorouracil, and leucovorin calcium (FOLFOX regimen) vs fluorouracil and cisplatin (Herskovic regimen) in patients with inoperable esophageal cancer. (Phase II)
- To assess the endoscopic complete response rate in patients treated with these regimens. (Phase II)
- To compare the event-free survival of patients treated with these regimens. (Phase III)
Secondary
- To assess the toxicity profile of these regimens using the NCI CTC v2.0 criteria. (Phase II)
- To compare the overall survival, endoscopic complete response rate, incidence of grade 3-4 toxicities, and time to treatment failure in patients treated with these regimens. (Phase III)
- To evaluate the quality of life of these patients using EORTC QLQ-C30 (version 3) and a validated disease-specific module EORTC QLQ-OES18. (Phase III)
OUTLINE: This is a multicenter study. Patients are stratified according to histological type (adenocarcinoma or adenosquamous carcinoma vs squamous cell carcinoma), pretreatment weight loss within the past 6 months (grade 1 [< 10%] vs grade 2 [≥ 10%]), ECOG performance status (0 vs 1 vs 2), and participating center. Patients are randomized to 1 of 2 treatment arms.
- Arm I (modified FOLFOX 4 regimen): Patients undergo radiotherapy 5 days a week for 5 weeks. Beginning concurrently with radiotherapy, patients receive oxaliplatin IV over 2 hours and leucovorin calcium IV over 2 hours on day 1 and fluorouracil IV continuously over 46 hours on days 1 and 2. Treatment with chemotherapy repeats every 2 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
- Arm II (Herskovic regimen): Patients undergo radiotherapy as in arm I. Patients also receive cisplatin IV continuously over 24 hours on day 1 and fluorouracil IV continuously over 96 hours on days 1-4 of weeks 1, 5, 8, and 11 in the absence of disease progression or unacceptable toxicity.
Quality of life is assessed at baseline, periodically during study therapy, and then every 6 months for 1 year and annually for 3 years after completion of study therapy.
After completion of study therapy, patients are followed at 4 weeks and then every 3-6 months until disease progression.
PROJECTED ACCRUAL: A total of 97 patients will be accrued for the phase II portion of the study. A total of 169 patients will be accrued for the phase III portion of the study.
연구 유형
등록 (실제)
단계
- 2 단계
- 3단계
연락처 및 위치
연구 장소
-
-
-
Besancon, 프랑스, 25030
- CHR de Besancon - Hopital Saint-Jacques
-
Bordeaux, 프랑스, 33076
- Institut Bergonie
-
Bordeaux, 프랑스, 33075
- Hopital Saint André
-
Boulogne-Billancourt, 프랑스, F-92104
- Hôpital Ambroise Paré
-
Caen, 프랑스, 14076
- Centre Regional Francois Baclesse
-
Caen, 프랑스, 14052
- Polyclinique du Parc
-
Dijon, 프랑스, 21034
- Hôpital du Bocage
-
Dijon, 프랑스, 21079
- Centre de Lutte Contre le Cancer Georges-Francois Leclerc
-
Lille, 프랑스, 59020
- Centre Oscar Lambret
-
Limoges, 프랑스, 87042
- Centre Hospital Regional Universitaire de Limoges
-
Lyon, 프랑스, 69373
- Centre Léon Bérard
-
Marseille, 프랑스, 13385
- CHU de la Timone
-
Montpellier, 프랑스, 34298
- Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle
-
Nice, 프랑스, 06189
- Centre Antoine Lacassagne
-
Paris, 프랑스, 75015
- Hôpital Europeén Georges Pompidou
-
Paris, 프랑스, 75970
- Hôpital Tenon
-
Paris, 프랑스, 75475
- Hôpital Saint-Louis
-
Poitiers, 프랑스, 86021
- CHU Poitiers
-
Reims, 프랑스, 51092
- CHU - Robert Debre
-
Reims, 프랑스, 51056
- Institut Jean Godinot
-
Rennes, 프랑스, 35042
- Centre Eugene Marquis
-
Rouen, 프랑스, 76031
- Hôpital Charles Nicolle
-
Saint Brieuc, 프랑스, F-22015
- Clinique Armoricaine de Radiologie
-
Strasbourg, 프랑스, 67065
- Centre Paul Strauss
-
Toulouse, 프랑스, 31052
- Institut Claudius Regaud
-
Toulouse, 프랑스, 31078
- Clinique du Parc
-
Vandoeuvre-les-Nancy, 프랑스, 54511
- Centre Alexis Vautrin
-
Villejuif, 프랑스, F-94805
- Institut Gustave Roussy
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
DISEASE CHARACTERISTICS:
Histologically proven adenocarcinoma, squamous cell carcinoma, or adenosquamous carcinoma of the esophagus
Locally advanced disease (any T, N0 or N1, M0 or M1a)
No metastatic disease, except for tumor involvement of the upper third of the esophagus or cervical esophageal tumor with regional nodes, or tumor involvement of the lower third of the esophagus with celiac nodes (M1a)
- Cervical primary tumor with positive supraclavicular or cervical lymph nodes (defined as N1) allowed
- No radiographic evidence of enlarged (≥ 1.5 cm) celiac lymph nodes by CT scan or echography
- No small cell or undifferentiated carcinoma of the esophagus
- No multiple carcinomas of the esophagus (i.e., > 1 esophageal tumor)
No cardia tumor (Siewert II) or gastric tumor extension to the esophagus (Siewert III)
- Esophageal tumor extension to the cardia (Siewert I) (center of the tumor lying > 1 cm-5 cm above gastroesophageal junction) allowed
- Inoperable disease OR surgery is contraindicated
- No tracheo-esophageal fistula or invasion of the tracheo-bronchial tree
PATIENT CHARACTERISTICS:
- ECOG performance status 0-2
- Life expectancy ≥ 3 months
- Absolute neutrophil count ≥ 1,500/mm³
- Platelet count ≥ 100,000/mm³
- Hemoglobin ≥ 10 g/dL (transfusion allowed)
- Creatinine < 15 mg/L
- Total bilirubin < 1.5 times upper limit of normal (ULN)
- ALT and AST < 2.5 times ULN
- Prothrombin time ≥ 60%
- Not pregnant or nursing
- Fertile patients must use effective contraception
- Caloric intake sufficient (i.e., > 1,000 Kcal/m²/day) (orally or with gastrostomy)
- No weight loss > 20% normal body weight within the past 3 months
- No complete dysphagia
- No exclusive requirement for parenteral nutrition
No peripheral neuropathy > grade 1
- No sensitive peripheral neuropathy with functional impairment
- No auditory disorders
- No other prior malignancies except curatively treated nonmelanoma skin cancer or carcinoma in situ of the cervix or stage I or II node-negative head and neck cancer that was curatively treated > 3 years ago
No myocardial infarction within the past 6 months
- Patients who have had a myocardial infarction > 6 months ago are eligible provided there is no transient ischemia by thallium myocardial scintigraphy and patient is able to undergo chemotherapy , as determined by a cardiologist
- No other serious illness or medical condition (e.g., symptomatic coronary disease, left ventricular failure, or uncontrolled infection)
- No stage II-IV arterial disease, according to the DE LERICHE and FONTAINE classification
- No geographical, social, or psychological circumstances preventing regular follow-up
PRIOR CONCURRENT THERAPY:
- No prior treatment for esophageal cancer (e.g., surgery, chemotherapy, or radiotherapy)
- No prior cervical, thoracic, or abdominal radiotherapy with field overlapping the proposed esophageal radiotherapy field
- More than 30 days since prior experimental drugs or participation in another clinical trial
- No other concurrent anticancer therapy
- No concurrent phenytoin or yellow fever vaccine
- No concurrent high-dose, long-term corticosteroids
- No concurrent calcium gluconate/magnesium sulfate infusions
- No concurrent hematopoietic growth factors
- No concurrent esophageal dilatation
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: FOLFOX and radiotherapy
Oxaliplatin (85mg/m2); Folinic Acid (200mg/m2); 5-FU (400mg/m2-Bolus and 1600mg/m2 over 46h)- once every two weeks for six cycles
|
다른 이름들:
|
|
실험적: 5-FU / cisplatin and radiotherapy
5-FU (100mg/m2); Cisplatin (75mg/m2)
|
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
|---|---|
|
Percentage of patients who complete the full study treatment (Phase II)
기간: 12 weeks
|
12 weeks
|
|
Endoscopic complete response rate (Phase II)
기간: 12 weeks
|
12 weeks
|
|
Progression-free survival (Phase III)
기간: Until progression
|
Until progression
|
2차 결과 측정
결과 측정 |
기간 |
|---|---|
|
Safety profile as assessed by NCI CTC v2.0 (Phase II)
기간: Total duration of the trial
|
Total duration of the trial
|
|
Overall survival (Phase III)
기간: Total duration of the trial
|
Total duration of the trial
|
|
Complete response rate (Phase III)
기간: Total duration of the trial
|
Total duration of the trial
|
|
Time to treatment failure (Phase III)
기간: Total duration of the trial
|
Total duration of the trial
|
|
Incidence of grade 3-4 toxicities (Phase III)
기간: Total duration of the trial
|
Total duration of the trial
|
|
Quality of life as assessed by EORTC QLQ-C30 (version 3) and EORTC QLQ-OES18 (Phase III)
기간: Total duration of the trial
|
Total duration of the trial
|
공동 작업자 및 조사자
스폰서
수사관
- 수석 연구원: Thierry Conroy, MD, Centre Alexis Vautrin
간행물 및 유용한 링크
일반 간행물
- Winter A, Cuer B, Conroy T, Juzyna B, Gourgou S, Mollevi C, Touraine C. Flexible modeling of longitudinal health-related quality of life data accounting for informative dropout in a cancer clinical trial. Qual Life Res. 2022 Sep 17. doi: 10.1007/s11136-022-03252-6. Online ahead of print.
- Cuer B, Conroy T, Juzyna B, Gourgou S, Mollevi C, Touraine C. Joint modelling with competing risks of dropout for longitudinal analysis of health-related quality of life in cancer clinical trials. Qual Life Res. 2022 May;31(5):1359-1370. doi: 10.1007/s11136-021-03040-8. Epub 2021 Nov 24.
- Cuer B, Mollevi C, Anota A, Charton E, Juzyna B, Conroy T, Touraine C. Handling informative dropout in longitudinal analysis of health-related quality of life: application of three approaches to data from the esophageal cancer clinical trial PRODIGE 5/ACCORD 17. BMC Med Res Methodol. 2020 Sep 3;20(1):223. doi: 10.1186/s12874-020-01104-w.
- Conroy T, Galais MP, Raoul JL, Bouche O, Gourgou-Bourgade S, Douillard JY, Etienne PL, Boige V, Martel-Lafay I, Michel P, Llacer-Moscardo C, Francois E, Crehange G, Abdelghani MB, Juzyna B, Bedenne L, Adenis A; Federation Francophone de Cancerologie Digestive and UNICANCER-GI Group. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial. Lancet Oncol. 2014 Mar;15(3):305-14. doi: 10.1016/S1470-2045(14)70028-2. Epub 2014 Feb 18. Erratum In: Lancet Oncol. 2014 Dec;15(13):e587. Lancet Oncol. 2014 Dec;15(13):e587.
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- CDR0000595050
- FRE-FNCLCC- ACCORD-17-0707
- EU-20848
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .